References
- Magerl W, Treede RD. Heat-evoked vasodilatation in human hairy skin: axon reflexes due to low-level activity of nociceptive afferents. J Physiol 1996;497(Pt 3):837-48
- Minson CT, Berry LT, Joyner MJ. Nitric oxide and neurally mediated regulation of skin blood flow during local heating. J Appl Physiol 2001;91:1619-26
- Kellogg DL Jr. In vivo mechanisms of cutaneous vasodilation and vasoconstriction in humans during thermoregulatory challenges. J Appl Physiol 2006;100:1709-18
- Koivisto VA. Sauna-induced acceleration in insulin absorption from subcutaneous injection site. Br Med J 1980;280:1411-13
- Raz I, Weiss R, Yegorchikov Y, et al. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther 2009;31:980-7
- Raz I, Yegorchikov Y, Bitton G, et al. Improving pharmacokinetic and pharmacodynamic profiles of rapid-acting insulin analogs using the InsuPatch device. J Diabetes Sci Technol 2009;3:384.A138
- Cengiz E, Tamborlane W, Sherr J, et al. Effect of a novel warming device on pharmacodynamics (PD) of rapid acting insulin in youth with type 1 diabetes (T1D). Diabetes Technol Ther 2011;13:173-293
- Freckmann G, Pleus S, Westhoff A, et al. Clinical performance of a device that applies local heat to the insulin infusion site: a crossover study. J Diabetes Sci Technol 2012;6:320-7
- Freckmann G, Pleus S, Haug A, et al. Increasing local blood flow by warming the application site: beneficial effects on postprandial glycemic excursions. J Diabetes Sci Technol 2012;6:780-5
- Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997;157:1249-55
- Danon A, Ben-Shimon S, Ben-Zvi Z. Effect of exercise and heat exposure on percutaneous absorption of methyl salicylate. Eur J Clin Pharmacol 1986;31:49-52
- Ashburn MA, Ogden LL, Zhang J, et al. The pharmaco-kinetics of transdermal fentanyl delivered with and without controlled heat. J Pain 2003;4:291-7
- Sindelka G, Heinemann L, Berger M, et al. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994;37:377-80
- Jakobsen LA, Jensen A, Larsen LE, et al. Effect of cutaneous blood flow on absorption of insulin: a methodological study in healthy male volunteers. Int J Physiol Pathophysiol Pharmacol 2011;3:257-65
- DCCT. Hypoglycemia in the Diabetes Control and Complications Trial. The Control and Complications Trial Research Group. Diabetes 1997;46:271-86
- DCCT. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995;18:1415-27
- The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-83
- Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997;46:265-70
- Pfützner A, Küstner E, Forst T, et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 1996;104:25-30
- Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902-12
- Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
- Jönsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health 2006;9:193-8
- Menzin J, Korn JR, Cohen J, et al. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm 2010;16:264-75